Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05NWF
|
||||
| Former ID |
DIB018757
|
||||
| Drug Name |
adenosine diphosphate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C10H15N5O10P2
|
||||
| InChI |
InChI=1S/C10H15N5O10P2/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(24-10)1-23-27(21,22)25-26(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1
|
||||
| InChIKey |
XTWYTFMLZFPYCI-KQYNXXCUSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
3310, 583708, 583773, 583911, 583921, 583922, 584175, 584188, 584204, 584229, 584302, 584513, 584515, 584599, 584626, 584627, 584628, 584632, 584641, 584643, 585456, 585517, 585721, 585872, 793510, 819880, 819957, 820163, 820296, 820360, 820365, 820433, 820439, 820507, 820515, 820541, 820600, 821195, 821592, 821838, 821868, 822043, 822090, 822091, 822116, 822129, 822159, 822163, 822165, 822167
|
||||
| Target and Pathway | |||||
| Target(s) | P2Y13 receptor | Target Info | Agonist | [2] | |
| P2Y purinoceptor 1 | Target Info | Agonist | [3] | ||
| P2Y purinoceptor 6 | Target Info | Agonist | [4] | ||
| TRPM4 | Target Info | Inhibitor (gating inhibitor) | [5] | ||
| P2Y purinoceptor 12 | Target Info | Agonist | [6] | ||
| KEGG Pathway | Rap1 signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Platelet activationhsa04080:Neuroactive ligand-receptor interactionhsa04611:Platelet activation | |||||
| Reactome | G alpha (q) signalling events | ||||
| P2Y receptors | |||||
| ADP signalling through P2Y purinoceptor 1R-HSA-416476:G alpha (q) signalling events | |||||
| P2Y receptorsR-HSA-417957:P2Y receptors | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Nucleotide GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Signal amplification | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP80:Nucleotide GPCRs | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1712). | ||||
| REF 2 | Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12. | ||||
| REF 3 | Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol. 2002 Nov;62(5):1249-57. | ||||
| REF 4 | Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8. | ||||
| REF 5 | Intracellular nucleotides and polyamines inhibit the Ca2+-activated cation channel TRPM4b. Pflugers Arch. 2004 Apr;448(1):70-5. Epub 2004 Jan 31. | ||||
| REF 6 | P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.